exon targeting guide rna Search Results


90
Broad Institute Inc guide rna (grna) sequences targeting the exon regions of the human il15ra gene
Guide Rna (Grna) Sequences Targeting The Exon Regions Of The Human Il15ra Gene, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exon+targeting+guide+rna/guide+rna++grna++sequences+targeting+the+exon+regions+of+the+human+il15ra+gene/pmc11986442-68-6-17
Average 90 stars, based on 1 article reviews
guide rna (grna) sequences targeting the exon regions of the human il15ra gene - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Biotechnology Information single guide rna targeting exon 2 of slc15a4
Single Guide Rna Targeting Exon 2 Of Slc15a4, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exon+targeting+guide+rna/single+guide+rna+targeting+exon+2+of+slc15a4/10__1016_slash_j__jia__2023__06__016-50-7-15
Average 90 stars, based on 1 article reviews
single guide rna targeting exon 2 of slc15a4 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sangon Biotech ampk-targeting single guide (sg) rna sequences
AMPK inhibition mediated the chemoresistance of AML cells induced by HS‐5 cells . (A) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on AML cells after treatment with 1 mM 5‐aminoimidazole‐4‐carboxamide ribonucleotide (AICAR) was measured by CCK‐8 assay. (B) The percentage of apoptotic cells of 24 h treatment with Ara‐C (The concentration of Ara‐C was 50 μM for HL‐60 cells and 5 μM for U937 cells) on AML cells after treatment with 1 mM AICAR was expressed as mean ± SD from 3 independent experiments. (C) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on AML cells after treatment with 5 μM Compound C was measured by CCK‐8 assay. (D) The percentage of apoptotic cells of 24 h treatment with Ara‐C (The concentration of Ara‐C was 50 μM for HL‐60 cells and 5 μM for U937 cells) on AML cells after treatment with 5 μM Compound C was expressed as mean ± SD from 3 independent experiments. (E) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on U937 cells knocked out for AMPK was measured by CCK‐8 assay. (F) The percentage of apoptotic cells of 24 h treatment with Ara‐C (The concentration of Ara‐C was 50μM for HL‐60 cells and 5 μM for U937 cells) on U937 cells knocked out for AMPK was expressed as mean ± SD from 3 independent experiments. (G) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on AMPK‐overexpressing U937 cells. (H) The percentage of apoptotic cells of 24 h treatment with Ara‐C on AMPK‐overexpressing U937 cells was expressed as mean ± SD from 3 independent experiments. The data represent the mean ± SD of 3 independent experiments with 3 replicates for each experiment. CON, wide type; NC, empty vector control; AMPK‐OE, AMPK overexpression; <t>AMPK‐sg1/2,</t> AMPK gene was knocked out. ns, no significant difference, * P < 0.05, ** P < 0.01, *** P < 0.001
Ampk Targeting Single Guide (Sg) Rna Sequences, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exon+targeting+guide+rna/ampk+targeting+single+guide++sg++rna+sequences++ampk+exon+1++sg1++5++gaagatcggccactacattc+3+++sg2++5+++tacattctgggtgacacgct+3++/pmc09544716-72-1-18
Average 90 stars, based on 1 article reviews
ampk-targeting single guide (sg) rna sequences - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Broad Institute Inc synonymous heterozygous exon variation ser105ser (exon 5, rs201860923)
AMPK inhibition mediated the chemoresistance of AML cells induced by HS‐5 cells . (A) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on AML cells after treatment with 1 mM 5‐aminoimidazole‐4‐carboxamide ribonucleotide (AICAR) was measured by CCK‐8 assay. (B) The percentage of apoptotic cells of 24 h treatment with Ara‐C (The concentration of Ara‐C was 50 μM for HL‐60 cells and 5 μM for U937 cells) on AML cells after treatment with 1 mM AICAR was expressed as mean ± SD from 3 independent experiments. (C) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on AML cells after treatment with 5 μM Compound C was measured by CCK‐8 assay. (D) The percentage of apoptotic cells of 24 h treatment with Ara‐C (The concentration of Ara‐C was 50 μM for HL‐60 cells and 5 μM for U937 cells) on AML cells after treatment with 5 μM Compound C was expressed as mean ± SD from 3 independent experiments. (E) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on U937 cells knocked out for AMPK was measured by CCK‐8 assay. (F) The percentage of apoptotic cells of 24 h treatment with Ara‐C (The concentration of Ara‐C was 50μM for HL‐60 cells and 5 μM for U937 cells) on U937 cells knocked out for AMPK was expressed as mean ± SD from 3 independent experiments. (G) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on AMPK‐overexpressing U937 cells. (H) The percentage of apoptotic cells of 24 h treatment with Ara‐C on AMPK‐overexpressing U937 cells was expressed as mean ± SD from 3 independent experiments. The data represent the mean ± SD of 3 independent experiments with 3 replicates for each experiment. CON, wide type; NC, empty vector control; AMPK‐OE, AMPK overexpression; <t>AMPK‐sg1/2,</t> AMPK gene was knocked out. ns, no significant difference, * P < 0.05, ** P < 0.01, *** P < 0.001
Synonymous Heterozygous Exon Variation Ser105ser (Exon 5, Rs201860923), supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exon+targeting+guide+rna/single+guide+rna+targeting+nup210+exon+5/pm26536448-62-9-27
Average 90 stars, based on 1 article reviews
synonymous heterozygous exon variation ser105ser (exon 5, rs201860923) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Benchling Inc single-stranded guide rnas (sgrnas) targeting exon 3 mouse uxs1
AMPK inhibition mediated the chemoresistance of AML cells induced by HS‐5 cells . (A) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on AML cells after treatment with 1 mM 5‐aminoimidazole‐4‐carboxamide ribonucleotide (AICAR) was measured by CCK‐8 assay. (B) The percentage of apoptotic cells of 24 h treatment with Ara‐C (The concentration of Ara‐C was 50 μM for HL‐60 cells and 5 μM for U937 cells) on AML cells after treatment with 1 mM AICAR was expressed as mean ± SD from 3 independent experiments. (C) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on AML cells after treatment with 5 μM Compound C was measured by CCK‐8 assay. (D) The percentage of apoptotic cells of 24 h treatment with Ara‐C (The concentration of Ara‐C was 50 μM for HL‐60 cells and 5 μM for U937 cells) on AML cells after treatment with 5 μM Compound C was expressed as mean ± SD from 3 independent experiments. (E) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on U937 cells knocked out for AMPK was measured by CCK‐8 assay. (F) The percentage of apoptotic cells of 24 h treatment with Ara‐C (The concentration of Ara‐C was 50μM for HL‐60 cells and 5 μM for U937 cells) on U937 cells knocked out for AMPK was expressed as mean ± SD from 3 independent experiments. (G) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on AMPK‐overexpressing U937 cells. (H) The percentage of apoptotic cells of 24 h treatment with Ara‐C on AMPK‐overexpressing U937 cells was expressed as mean ± SD from 3 independent experiments. The data represent the mean ± SD of 3 independent experiments with 3 replicates for each experiment. CON, wide type; NC, empty vector control; AMPK‐OE, AMPK overexpression; <t>AMPK‐sg1/2,</t> AMPK gene was knocked out. ns, no significant difference, * P < 0.05, ** P < 0.01, *** P < 0.001
Single Stranded Guide Rnas (Sgrnas) Targeting Exon 3 Mouse Uxs1, supplied by Benchling Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exon+targeting+guide+rna/sg+rna+sequences+targeting+upstream+downstream+slc35a2+exon+3/pm32768525-52-10-21
Average 90 stars, based on 1 article reviews
single-stranded guide rnas (sgrnas) targeting exon 3 mouse uxs1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
CARBOMER INC aon targeting exon 73 of col7a1 rna
New and repurposed drugs for different genodermatoses, based on pathophysiology (ongoing trials mentioned in clinicaltrials.gov with NCT).
Aon Targeting Exon 73 Of Col7a1 Rna, supplied by CARBOMER INC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exon+targeting+guide+rna/aon+targeting+exon+73+of+col7a1+rna/pmc08766835-125-8-12
Average 90 stars, based on 1 article reviews
aon targeting exon 73 of col7a1 rna - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Synthego Inc short guide rna oligonucleotides targeting exon 17 of nup98-96
New and repurposed drugs for different genodermatoses, based on pathophysiology (ongoing trials mentioned in clinicaltrials.gov with NCT).
Short Guide Rna Oligonucleotides Targeting Exon 17 Of Nup98 96, supplied by Synthego Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exon+targeting+guide+rna/short+guide+rna+oligonucleotides+targeting+exon+17+of+nup98+96/pmc12267526-307-8-12
Average 90 stars, based on 1 article reviews
short guide rna oligonucleotides targeting exon 17 of nup98-96 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Synthego Inc exon-targeting single guide rna (tttcggtaccttcgccctcg)
New and repurposed drugs for different genodermatoses, based on pathophysiology (ongoing trials mentioned in clinicaltrials.gov with NCT).
Exon Targeting Single Guide Rna (Tttcggtaccttcgccctcg), supplied by Synthego Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exon+targeting+guide+rna/exon+targeting+single+guide+rna++tttcggtaccttcgccctcg+/pmc11695602-238-27-35
Average 90 stars, based on 1 article reviews
exon-targeting single guide rna (tttcggtaccttcgccctcg) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Macrogen exon target capture rna-seq
New and repurposed drugs for different genodermatoses, based on pathophysiology (ongoing trials mentioned in clinicaltrials.gov with NCT).
Exon Target Capture Rna Seq, supplied by Macrogen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exon+targeting+guide+rna/exon+target+capture+rna+seq/pmc10035512-38-0-10
Average 90 stars, based on 1 article reviews
exon target capture rna-seq - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
ToolGen Incorporated guide rna targeting the dna binding domain at second exon of hsf5
New and repurposed drugs for different genodermatoses, based on pathophysiology (ongoing trials mentioned in clinicaltrials.gov with NCT).
Guide Rna Targeting The Dna Binding Domain At Second Exon Of Hsf5, supplied by ToolGen Incorporated, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exon+targeting+guide+rna/guide+rna+targeting+the+dna+binding+domain+at+second+exon+of+hsf5/pm30566854-215-13-23
Average 90 stars, based on 1 article reviews
guide rna targeting the dna binding domain at second exon of hsf5 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

86
Synthego Inc single guide sg rna targeting endogenous human dnm1l exon 1
a Mutation information and representative MRI images of two patients. The T2 axial view of patient 1 was taken at the age of 3 years and 9 months. The FLAIR axial view of patient 2 was taken at the age of 1 year and 10 months, with increased signal intensity indicating atrophic change. b Cross-species conservation of protein sequences near the mutation residue. c The structure of the DRP1 tetramer (PDB, 4BEJ) shown as a ribbon diagram, with each protomer colored differently. Mutated residues are highlighted as sticks and labeled in a zoom-in box. L650 (UniProt ID, O00429-1) corresponds to L624 in <t>DNM1L</t> isoform 2 (UniProt ID, O00429-3) in the displayed structure. d Perturbation modeling of previously reported (G350R and G362S) and novel (L416P and L650R) DNM1L mutants using FoldX. A, B, C and D represent chain IDs in the tetramer structure, while AB, ABC and ABCD correspond to the dimer, trimer and tetramer, respectively. e Representative images of mitochondrial morphology in human NPCs transfected with DNM1L variants. Red, Mitotracker CMXRos; green, GFP; blue, DAPI. Scale bar, 10 μm. f Quantification of mitochondrial morphology in human NPCs transfected with DNM1L variants. n = 3 with at least 60 cells in each condition analyzed for an independent experiment. g Representative images of peroxisomal morphology in human NPCs transfected with DNM1L variants. Red, PMP70; green, GFP; blue, DAPI. Scale bar, 20 μm. h Quantification of peroxisomal morphology in human NPCs transfected with DNM1L variants. Control, n = 21; wild type, n = 34; G350R, n = 25; L416P, n = 31; L650R, n = 40. Bar graphs indicate mean ± s.e.m. Statistical significance is determined by two-way ANOVA with Tukey’s post hoc test for e and the Kruskal–Wallis test with Dunn’s post hoc test for h . ** P < 0.01; *** P < 0.001; **** P < 0.0001.
Single Guide Sg Rna Targeting Endogenous Human Dnm1l Exon 1, supplied by Synthego Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exon+targeting+guide+rna/1+dnm1l+endogenous+exon+guide+human+rna+sg+single+targeting/pmc13049093-42-0-11
Average 86 stars, based on 1 article reviews
single guide sg rna targeting endogenous human dnm1l exon 1 - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

Image Search Results


AMPK inhibition mediated the chemoresistance of AML cells induced by HS‐5 cells . (A) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on AML cells after treatment with 1 mM 5‐aminoimidazole‐4‐carboxamide ribonucleotide (AICAR) was measured by CCK‐8 assay. (B) The percentage of apoptotic cells of 24 h treatment with Ara‐C (The concentration of Ara‐C was 50 μM for HL‐60 cells and 5 μM for U937 cells) on AML cells after treatment with 1 mM AICAR was expressed as mean ± SD from 3 independent experiments. (C) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on AML cells after treatment with 5 μM Compound C was measured by CCK‐8 assay. (D) The percentage of apoptotic cells of 24 h treatment with Ara‐C (The concentration of Ara‐C was 50 μM for HL‐60 cells and 5 μM for U937 cells) on AML cells after treatment with 5 μM Compound C was expressed as mean ± SD from 3 independent experiments. (E) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on U937 cells knocked out for AMPK was measured by CCK‐8 assay. (F) The percentage of apoptotic cells of 24 h treatment with Ara‐C (The concentration of Ara‐C was 50μM for HL‐60 cells and 5 μM for U937 cells) on U937 cells knocked out for AMPK was expressed as mean ± SD from 3 independent experiments. (G) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on AMPK‐overexpressing U937 cells. (H) The percentage of apoptotic cells of 24 h treatment with Ara‐C on AMPK‐overexpressing U937 cells was expressed as mean ± SD from 3 independent experiments. The data represent the mean ± SD of 3 independent experiments with 3 replicates for each experiment. CON, wide type; NC, empty vector control; AMPK‐OE, AMPK overexpression; AMPK‐sg1/2, AMPK gene was knocked out. ns, no significant difference, * P < 0.05, ** P < 0.01, *** P < 0.001

Journal: Journal of Leukocyte Biology

Article Title: Bone marrow microenvironment drives AML cell OXPHOS addiction and AMPK inhibition to resist chemotherapy

doi: 10.1002/JLB.6A0821-409RR

Figure Lengend Snippet: AMPK inhibition mediated the chemoresistance of AML cells induced by HS‐5 cells . (A) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on AML cells after treatment with 1 mM 5‐aminoimidazole‐4‐carboxamide ribonucleotide (AICAR) was measured by CCK‐8 assay. (B) The percentage of apoptotic cells of 24 h treatment with Ara‐C (The concentration of Ara‐C was 50 μM for HL‐60 cells and 5 μM for U937 cells) on AML cells after treatment with 1 mM AICAR was expressed as mean ± SD from 3 independent experiments. (C) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on AML cells after treatment with 5 μM Compound C was measured by CCK‐8 assay. (D) The percentage of apoptotic cells of 24 h treatment with Ara‐C (The concentration of Ara‐C was 50 μM for HL‐60 cells and 5 μM for U937 cells) on AML cells after treatment with 5 μM Compound C was expressed as mean ± SD from 3 independent experiments. (E) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on U937 cells knocked out for AMPK was measured by CCK‐8 assay. (F) The percentage of apoptotic cells of 24 h treatment with Ara‐C (The concentration of Ara‐C was 50μM for HL‐60 cells and 5 μM for U937 cells) on U937 cells knocked out for AMPK was expressed as mean ± SD from 3 independent experiments. (G) Growth inhibitory effect of 24 h treatment with different concentrations of Ara‐C and DNR on AMPK‐overexpressing U937 cells. (H) The percentage of apoptotic cells of 24 h treatment with Ara‐C on AMPK‐overexpressing U937 cells was expressed as mean ± SD from 3 independent experiments. The data represent the mean ± SD of 3 independent experiments with 3 replicates for each experiment. CON, wide type; NC, empty vector control; AMPK‐OE, AMPK overexpression; AMPK‐sg1/2, AMPK gene was knocked out. ns, no significant difference, * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: The AMPK‐targeting single guide (sg) RNA sequences ( AMPK exon 1, sg1: 5′‐GAAGATCGGCCACTACATTC‐3′; sg2: 5′‐TACATTCTGGGTGACACGCT‐3′) were synthesized by Sangon Biotech (Shanghai, China).

Techniques: Inhibition, CCK-8 Assay, Concentration Assay, Plasmid Preparation, Control, Over Expression

AMPK inhibition increases mTORC1 activity and c‐Myc proteins expression . (A) Representative western blot analysis of AMPK‐mTORC1 pathway proteins (total AMPK, p‐AMPK T172 , total p70S6K, p‐p70S6K T389 , total 4E‐BP1, p‐4E‐BP1 S65 , and c‐Myc; β‐actin was used as loading control) of AMPK‐overexpressing U937 cells. (B) Representative western blot analysis of AMPK‐mTORC1 pathway proteins in U937 cells knocked out for AMPK expression. (C) Representative western blot analysis of AMPK‐mTORC1 pathway proteins from AML cells after treatment with 1 mM AICAR. (D) Representative western blot analysis of AMPK‐mTORC1 pathway proteins in AML cells after treatment with 5 μM Compound C. WT, wide type; NC, empty vector control; AMPK‐OE, AMPK overexpression; AMPK‐sg1/2, AMPK gene was knocked out. The representative images of 3 independent experiments were used

Journal: Journal of Leukocyte Biology

Article Title: Bone marrow microenvironment drives AML cell OXPHOS addiction and AMPK inhibition to resist chemotherapy

doi: 10.1002/JLB.6A0821-409RR

Figure Lengend Snippet: AMPK inhibition increases mTORC1 activity and c‐Myc proteins expression . (A) Representative western blot analysis of AMPK‐mTORC1 pathway proteins (total AMPK, p‐AMPK T172 , total p70S6K, p‐p70S6K T389 , total 4E‐BP1, p‐4E‐BP1 S65 , and c‐Myc; β‐actin was used as loading control) of AMPK‐overexpressing U937 cells. (B) Representative western blot analysis of AMPK‐mTORC1 pathway proteins in U937 cells knocked out for AMPK expression. (C) Representative western blot analysis of AMPK‐mTORC1 pathway proteins from AML cells after treatment with 1 mM AICAR. (D) Representative western blot analysis of AMPK‐mTORC1 pathway proteins in AML cells after treatment with 5 μM Compound C. WT, wide type; NC, empty vector control; AMPK‐OE, AMPK overexpression; AMPK‐sg1/2, AMPK gene was knocked out. The representative images of 3 independent experiments were used

Article Snippet: The AMPK‐targeting single guide (sg) RNA sequences ( AMPK exon 1, sg1: 5′‐GAAGATCGGCCACTACATTC‐3′; sg2: 5′‐TACATTCTGGGTGACACGCT‐3′) were synthesized by Sangon Biotech (Shanghai, China).

Techniques: Inhibition, Activity Assay, Expressing, Western Blot, Control, Plasmid Preparation, Over Expression

AMPK knockout cells promoted AML progression and chemoresistance in mice . (A) Hematoxylin and eosin (HE) staining of the femurs from NCG mice. Scale bar, 50 μM. (B) Immunofluorescence (IF) staining for human CD45 (green) expression and nuclei marker (DAPI, blue) in the femurs of NCG mice. Scale bar, 50 μM. (C) Representative FCM profiles of human CD45 surface marker expression in AML cells of femurs. (D) Each data point represents the proportion of human CD45 + cells in the femurs per mouse (n = 5). (E‐F) Spleen anatomy (E) and weight (F) in the control, U937 WT , U937 NC‐sg , and U937 AMPK‐sg1 mice (n = 5). (G‐H) Each data point represents the proportion of human CD45 + cells in the spleens (G) and livers (H) per mouse (n = 4). (I) Each data point represents the proportion of residual human CD45 + cells in the femur, spleen, and liver per mouse after Ara‐C treatment (n = 4). (J) The relative number of human CD45 + cells after Ara‐C treatment was normalized to vehicle‐treated controls. WT, wide type; NC‐sg, empty vector control; AMPK‐sg1, AMPK gene was knocked out. ns, no significant difference, * P < 0.05, ** P < 0.01, *** P < 0.001

Journal: Journal of Leukocyte Biology

Article Title: Bone marrow microenvironment drives AML cell OXPHOS addiction and AMPK inhibition to resist chemotherapy

doi: 10.1002/JLB.6A0821-409RR

Figure Lengend Snippet: AMPK knockout cells promoted AML progression and chemoresistance in mice . (A) Hematoxylin and eosin (HE) staining of the femurs from NCG mice. Scale bar, 50 μM. (B) Immunofluorescence (IF) staining for human CD45 (green) expression and nuclei marker (DAPI, blue) in the femurs of NCG mice. Scale bar, 50 μM. (C) Representative FCM profiles of human CD45 surface marker expression in AML cells of femurs. (D) Each data point represents the proportion of human CD45 + cells in the femurs per mouse (n = 5). (E‐F) Spleen anatomy (E) and weight (F) in the control, U937 WT , U937 NC‐sg , and U937 AMPK‐sg1 mice (n = 5). (G‐H) Each data point represents the proportion of human CD45 + cells in the spleens (G) and livers (H) per mouse (n = 4). (I) Each data point represents the proportion of residual human CD45 + cells in the femur, spleen, and liver per mouse after Ara‐C treatment (n = 4). (J) The relative number of human CD45 + cells after Ara‐C treatment was normalized to vehicle‐treated controls. WT, wide type; NC‐sg, empty vector control; AMPK‐sg1, AMPK gene was knocked out. ns, no significant difference, * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: The AMPK‐targeting single guide (sg) RNA sequences ( AMPK exon 1, sg1: 5′‐GAAGATCGGCCACTACATTC‐3′; sg2: 5′‐TACATTCTGGGTGACACGCT‐3′) were synthesized by Sangon Biotech (Shanghai, China).

Techniques: Knock-Out, Staining, Immunofluorescence, Expressing, Marker, Control, Plasmid Preparation

New and repurposed drugs for different genodermatoses, based on pathophysiology (ongoing trials mentioned in clinicaltrials.gov with NCT).

Journal: Frontiers in Pharmacology

Article Title: Challenges in Treating Genodermatoses: New Therapies at the Horizon

doi: 10.3389/fphar.2021.746664

Figure Lengend Snippet: New and repurposed drugs for different genodermatoses, based on pathophysiology (ongoing trials mentioned in clinicaltrials.gov with NCT).

Article Snippet: , NCT03605069 , AON targeting exon 73 of COL7A1 RNA in a carbomer-based hydrogel (Q313).

Techniques: Cream, Activation Assay, Over Expression, Protease Inhibitor, Expressing, Activity Assay, Control, Gene Expression

Treatments under investigation aiming to restore protein expression (ongoing trials mentioned in clinicaltrials.gov with NCT)

Journal: Frontiers in Pharmacology

Article Title: Challenges in Treating Genodermatoses: New Therapies at the Horizon

doi: 10.3389/fphar.2021.746664

Figure Lengend Snippet: Treatments under investigation aiming to restore protein expression (ongoing trials mentioned in clinicaltrials.gov with NCT)

Article Snippet: , NCT03605069 , AON targeting exon 73 of COL7A1 RNA in a carbomer-based hydrogel (Q313).

Techniques: Expressing, Activity Assay, Immunopeptidomics, Mutagenesis, Protease Inhibitor, Formulation

Cell and gene therapies under investigation for genodermatoses mentioned in clinicaltrials.gov with NCT.

Journal: Frontiers in Pharmacology

Article Title: Challenges in Treating Genodermatoses: New Therapies at the Horizon

doi: 10.3389/fphar.2021.746664

Figure Lengend Snippet: Cell and gene therapies under investigation for genodermatoses mentioned in clinicaltrials.gov with NCT.

Article Snippet: , NCT03605069 , AON targeting exon 73 of COL7A1 RNA in a carbomer-based hydrogel (Q313).

Techniques: Ex Vivo, Derivative Assay, In Situ, In Vivo, Virus, Plasmid Preparation, Expressing, Generated, Genetically Modified

a Mutation information and representative MRI images of two patients. The T2 axial view of patient 1 was taken at the age of 3 years and 9 months. The FLAIR axial view of patient 2 was taken at the age of 1 year and 10 months, with increased signal intensity indicating atrophic change. b Cross-species conservation of protein sequences near the mutation residue. c The structure of the DRP1 tetramer (PDB, 4BEJ) shown as a ribbon diagram, with each protomer colored differently. Mutated residues are highlighted as sticks and labeled in a zoom-in box. L650 (UniProt ID, O00429-1) corresponds to L624 in DNM1L isoform 2 (UniProt ID, O00429-3) in the displayed structure. d Perturbation modeling of previously reported (G350R and G362S) and novel (L416P and L650R) DNM1L mutants using FoldX. A, B, C and D represent chain IDs in the tetramer structure, while AB, ABC and ABCD correspond to the dimer, trimer and tetramer, respectively. e Representative images of mitochondrial morphology in human NPCs transfected with DNM1L variants. Red, Mitotracker CMXRos; green, GFP; blue, DAPI. Scale bar, 10 μm. f Quantification of mitochondrial morphology in human NPCs transfected with DNM1L variants. n = 3 with at least 60 cells in each condition analyzed for an independent experiment. g Representative images of peroxisomal morphology in human NPCs transfected with DNM1L variants. Red, PMP70; green, GFP; blue, DAPI. Scale bar, 20 μm. h Quantification of peroxisomal morphology in human NPCs transfected with DNM1L variants. Control, n = 21; wild type, n = 34; G350R, n = 25; L416P, n = 31; L650R, n = 40. Bar graphs indicate mean ± s.e.m. Statistical significance is determined by two-way ANOVA with Tukey’s post hoc test for e and the Kruskal–Wallis test with Dunn’s post hoc test for h . ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Journal: Experimental & Molecular Medicine

Article Title: Reversibility and therapeutic feasibility of DNM1L -associated neurodevelopmental disorders

doi: 10.1038/s12276-026-01660-z

Figure Lengend Snippet: a Mutation information and representative MRI images of two patients. The T2 axial view of patient 1 was taken at the age of 3 years and 9 months. The FLAIR axial view of patient 2 was taken at the age of 1 year and 10 months, with increased signal intensity indicating atrophic change. b Cross-species conservation of protein sequences near the mutation residue. c The structure of the DRP1 tetramer (PDB, 4BEJ) shown as a ribbon diagram, with each protomer colored differently. Mutated residues are highlighted as sticks and labeled in a zoom-in box. L650 (UniProt ID, O00429-1) corresponds to L624 in DNM1L isoform 2 (UniProt ID, O00429-3) in the displayed structure. d Perturbation modeling of previously reported (G350R and G362S) and novel (L416P and L650R) DNM1L mutants using FoldX. A, B, C and D represent chain IDs in the tetramer structure, while AB, ABC and ABCD correspond to the dimer, trimer and tetramer, respectively. e Representative images of mitochondrial morphology in human NPCs transfected with DNM1L variants. Red, Mitotracker CMXRos; green, GFP; blue, DAPI. Scale bar, 10 μm. f Quantification of mitochondrial morphology in human NPCs transfected with DNM1L variants. n = 3 with at least 60 cells in each condition analyzed for an independent experiment. g Representative images of peroxisomal morphology in human NPCs transfected with DNM1L variants. Red, PMP70; green, GFP; blue, DAPI. Scale bar, 20 μm. h Quantification of peroxisomal morphology in human NPCs transfected with DNM1L variants. Control, n = 21; wild type, n = 34; G350R, n = 25; L416P, n = 31; L650R, n = 40. Bar graphs indicate mean ± s.e.m. Statistical significance is determined by two-way ANOVA with Tukey’s post hoc test for e and the Kruskal–Wallis test with Dunn’s post hoc test for h . ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Article Snippet: Single-guide (sg)RNA targeting endogenous human DNM1L exon 1 was designed with Synthego online tool (Supplementary Table ).

Techniques: Mutagenesis, Residue, Labeling, Transfection, Control

a , b , Representative images and quantification of GFP signal in postnatal brain slices electroporated with control vector or DNM1L G350R . IUE timelines are indicated above. Black, GFP. Scale bar, 100 μm. b Quantification of GFP + area ratio (G350R/control) in postnatal brain slices. n = 5. c , d Representative images and quantification of P7 mouse brain sections immunostained for CC3. Black arrows indicate positive cells. Black, CC3. Scale bar, 200 μm. n = 5. e IUE scheme for piggyBac system to label neurons and glia. f , g Representative images and quantification of P7 mouse brain sections electroporated with piggyBac system and immunostained with anti-GFP. Black, GFP. Scale bar, 200 μm. n = 4. Bar plot indicates mean ± s.e.m. Statistical significance is determined by the Kruskal–Wallis test with Dunn’s post hoc test for b , the Mann–Whitney test for d and one-way ANOVA with Dunnett’s post hoc test for g . ** P < 0.01; *** P < 0.001; **** P < 0.0001; n.s., not significant. Panel e created with BioRender.com .

Journal: Experimental & Molecular Medicine

Article Title: Reversibility and therapeutic feasibility of DNM1L -associated neurodevelopmental disorders

doi: 10.1038/s12276-026-01660-z

Figure Lengend Snippet: a , b , Representative images and quantification of GFP signal in postnatal brain slices electroporated with control vector or DNM1L G350R . IUE timelines are indicated above. Black, GFP. Scale bar, 100 μm. b Quantification of GFP + area ratio (G350R/control) in postnatal brain slices. n = 5. c , d Representative images and quantification of P7 mouse brain sections immunostained for CC3. Black arrows indicate positive cells. Black, CC3. Scale bar, 200 μm. n = 5. e IUE scheme for piggyBac system to label neurons and glia. f , g Representative images and quantification of P7 mouse brain sections electroporated with piggyBac system and immunostained with anti-GFP. Black, GFP. Scale bar, 200 μm. n = 4. Bar plot indicates mean ± s.e.m. Statistical significance is determined by the Kruskal–Wallis test with Dunn’s post hoc test for b , the Mann–Whitney test for d and one-way ANOVA with Dunnett’s post hoc test for g . ** P < 0.01; *** P < 0.001; **** P < 0.0001; n.s., not significant. Panel e created with BioRender.com .

Article Snippet: Single-guide (sg)RNA targeting endogenous human DNM1L exon 1 was designed with Synthego online tool (Supplementary Table ).

Techniques: Control, Plasmid Preparation, MANN-WHITNEY

a Scheme of RNA sequencing sampling from DNM1L iKO NPCs and differentiated neurons. Cells were treated with DMSO (DNM1L ON ) or DOX (DNM1L OFF ) during culture. b , c Functional enrichment analysis of upregulated and downregulated DEGs between DNM1L OFF and DNM1L ON conditions in NPCs ( b ) and neurons ( c ). The bar color indicates the cluster categories of the GO term. d Representative images of neurospheres immunostained with CC3. Red, CC3; blue, DAPI. Scale bar, 50 μm. e Quantification of neurospheres immunostained with CC3. Control Dox−, n = 22; control Dox+, n = 31; DNM1L iKO Dox−, n = 26; DNM1L iKO Dox+, n = 31. f RRHO analysis. The overlap of gene expression alterations by DNM1 L dysfunction ( x axis, DNM1L OFF versus DNM1L ON ) and by neuronal differentiation ( y axis) was compared. Genes were ordered on the basis of their Wald test statistics (log 2 fold change divided by the standard error of the log 2 fold change). Each point on the plot indicates the significance level of the overlap between the two ranked gene lists. Bar graphs indicate mean ± s.e.m. Statistical significance is determined by Brown–Forsythe and Welch ANOVA with Dunnett’s T3 post hoc test for e . **** P < 0.0001.

Journal: Experimental & Molecular Medicine

Article Title: Reversibility and therapeutic feasibility of DNM1L -associated neurodevelopmental disorders

doi: 10.1038/s12276-026-01660-z

Figure Lengend Snippet: a Scheme of RNA sequencing sampling from DNM1L iKO NPCs and differentiated neurons. Cells were treated with DMSO (DNM1L ON ) or DOX (DNM1L OFF ) during culture. b , c Functional enrichment analysis of upregulated and downregulated DEGs between DNM1L OFF and DNM1L ON conditions in NPCs ( b ) and neurons ( c ). The bar color indicates the cluster categories of the GO term. d Representative images of neurospheres immunostained with CC3. Red, CC3; blue, DAPI. Scale bar, 50 μm. e Quantification of neurospheres immunostained with CC3. Control Dox−, n = 22; control Dox+, n = 31; DNM1L iKO Dox−, n = 26; DNM1L iKO Dox+, n = 31. f RRHO analysis. The overlap of gene expression alterations by DNM1 L dysfunction ( x axis, DNM1L OFF versus DNM1L ON ) and by neuronal differentiation ( y axis) was compared. Genes were ordered on the basis of their Wald test statistics (log 2 fold change divided by the standard error of the log 2 fold change). Each point on the plot indicates the significance level of the overlap between the two ranked gene lists. Bar graphs indicate mean ± s.e.m. Statistical significance is determined by Brown–Forsythe and Welch ANOVA with Dunnett’s T3 post hoc test for e . **** P < 0.0001.

Article Snippet: Single-guide (sg)RNA targeting endogenous human DNM1L exon 1 was designed with Synthego online tool (Supplementary Table ).

Techniques: RNA Sequencing, Sampling, Functional Assay, Control, Gene Expression

a Schematic diagram of rescue conditions. Red arrows indicate DOX treatment during culture. b Heat map of sample-to-sample distances based on variance-stabilized transformation of read count data for total gene expression. The clustering of RNA sequencing samples illustrates the genetic relationships, as indicated by the intensities of the square colors. c Overlapped DEGs between the indicated comparison groups are shown as a Venn diagram. DEGs of each group were identified by comparison with the DNM1L ON group. Restored and persistent DEGs in DNM1L OFF condition are filled with green and pink, respectively. d , e Heat maps (left) and functional enrichment analysis (right) of persistent ( d ) and restored ( e ) DEGs. The color gradient in the heat map represents the Z score. Functional enrichment of upregulated and downregulated genes was shown in separate bar plots. The bar color indicates the cluster categories of the GO term.

Journal: Experimental & Molecular Medicine

Article Title: Reversibility and therapeutic feasibility of DNM1L -associated neurodevelopmental disorders

doi: 10.1038/s12276-026-01660-z

Figure Lengend Snippet: a Schematic diagram of rescue conditions. Red arrows indicate DOX treatment during culture. b Heat map of sample-to-sample distances based on variance-stabilized transformation of read count data for total gene expression. The clustering of RNA sequencing samples illustrates the genetic relationships, as indicated by the intensities of the square colors. c Overlapped DEGs between the indicated comparison groups are shown as a Venn diagram. DEGs of each group were identified by comparison with the DNM1L ON group. Restored and persistent DEGs in DNM1L OFF condition are filled with green and pink, respectively. d , e Heat maps (left) and functional enrichment analysis (right) of persistent ( d ) and restored ( e ) DEGs. The color gradient in the heat map represents the Z score. Functional enrichment of upregulated and downregulated genes was shown in separate bar plots. The bar color indicates the cluster categories of the GO term.

Article Snippet: Single-guide (sg)RNA targeting endogenous human DNM1L exon 1 was designed with Synthego online tool (Supplementary Table ).

Techniques: Transformation Assay, Gene Expression, RNA Sequencing, Comparison, Functional Assay

a Scatter plot presenting reversibility of Reactome pathways, color-coded by keyword and sized by gene set size. The x axis is the percentage of reversible genes among the Reactome pathway gene sets, and the y axis is the difference in the extent of change caused by DNM1L dysfunction and under rescue conditions compared with control, expressed as a Z score. b Heat map of PPAR–PGC1α signaling pathway genes in different conditions. The color gradient represents Z scores. c Scheme of mimicking reversible effects by overexpressing the mitochondrial biogenesis master regulator PPARGC1A . d , e Representative images and quantification of P7 PPARGC1A -coexpressing mouse brain sections immunostained with anti-GFP. Black, GFP. Scale bar, 100 μm. n = 5. f , g Representative images and quantification of mouse primary cortical neurons electroporated with control or DNM1L G350R , treated with DMSO vehicle or bezafibrate. Green, GFP. Scale bar, 50 μm. The viability of mouse primary cortical neurons was compared with the starting point DIV 4. n = 6 from two independent experiments for all conditions. h Scheme of bezafibrate administration during the perinatal period. i , j Representative images of P7 mouse brain sections treated with DMSO vehicle or bezafibrate and immunostained with anti-GFP. Black, GFP. Scale bar, 100 μm. n = 5. Bar graphs indicate mean ± s.e.m. Statistical significance is determined by one-way ANOVA with Tukey’s post hoc test for e and j and two-way ANOVA with Bonferroni’s post hoc test for g . * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Panels c and h created with BioRender.com .

Journal: Experimental & Molecular Medicine

Article Title: Reversibility and therapeutic feasibility of DNM1L -associated neurodevelopmental disorders

doi: 10.1038/s12276-026-01660-z

Figure Lengend Snippet: a Scatter plot presenting reversibility of Reactome pathways, color-coded by keyword and sized by gene set size. The x axis is the percentage of reversible genes among the Reactome pathway gene sets, and the y axis is the difference in the extent of change caused by DNM1L dysfunction and under rescue conditions compared with control, expressed as a Z score. b Heat map of PPAR–PGC1α signaling pathway genes in different conditions. The color gradient represents Z scores. c Scheme of mimicking reversible effects by overexpressing the mitochondrial biogenesis master regulator PPARGC1A . d , e Representative images and quantification of P7 PPARGC1A -coexpressing mouse brain sections immunostained with anti-GFP. Black, GFP. Scale bar, 100 μm. n = 5. f , g Representative images and quantification of mouse primary cortical neurons electroporated with control or DNM1L G350R , treated with DMSO vehicle or bezafibrate. Green, GFP. Scale bar, 50 μm. The viability of mouse primary cortical neurons was compared with the starting point DIV 4. n = 6 from two independent experiments for all conditions. h Scheme of bezafibrate administration during the perinatal period. i , j Representative images of P7 mouse brain sections treated with DMSO vehicle or bezafibrate and immunostained with anti-GFP. Black, GFP. Scale bar, 100 μm. n = 5. Bar graphs indicate mean ± s.e.m. Statistical significance is determined by one-way ANOVA with Tukey’s post hoc test for e and j and two-way ANOVA with Bonferroni’s post hoc test for g . * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Panels c and h created with BioRender.com .

Article Snippet: Single-guide (sg)RNA targeting endogenous human DNM1L exon 1 was designed with Synthego online tool (Supplementary Table ).

Techniques: Control